Deutsch
English
Español
Français
Nederlands
Português
What is the US-UK Pharmaceutical Trade Deal?
The US-UK pharmaceutical trade agreement, signed as part of the broader US-UK Economic Prosperity Deal (EPD) in December 2025, requires the United Kingdom to significantly increase spending on innovative medicines. In exchange, the United States exempts UK-origin pharmaceuticals from steep import tariffs that could otherwise reach 100%. The deal, finalized in principle on December 1, 2025, and formally published in April 2026, commits the UK to raising its spending on new medicines from 0.3% to 0.6% of GDP by 2036, increasing net prices paid by the NHS for new drugs by 25%, and reducing the VPAG rebate rate to 15%.
According to a detailed analysis published in the British Medical Journal (BMJ), the deal could cost the National Health Service (NHS) up to £44.7 billion between 2026 and 2036. The researchers estimate this diversion of funds could lead to 229,000 additional avoidable deaths over the same period. The UK pharmaceutical pricing agreement has sparked intense debate about the balance between trade benefits and public health.
Background: How the Deal Came About
The agreement emerged from post-Brexit trade negotiations between the UK and the US. President Donald Trump had long criticised the UK's pharmaceutical pricing system, arguing that American companies were not being fairly compensated for their innovations. Trump threatened to impose 100% import tariffs on UK-made medicines unless the UK agreed to pay more for US-developed drugs. The UK government, seeking to protect its pharmaceutical export sector and secure a broader trade deal, agreed to the terms in December 2025.
The deal's key provisions include:
- A 25% increase in net prices for new medicines paid by the NHS, starting April 2026
- Doubling of UK spending on innovative medicines from 0.3% to 0.6% of GDP by 2036
- Raising the NHS medicines budget from 10% to 12% of total NHS spending
- Increasing the NICE QALY threshold to between £25,000 and £35,000
- Reducing the VPAG rebate rate to 15% in 2026
In return, the US agreed to exempt UK-origin pharmaceuticals from Section 232 tariffs and to refrain from targeting UK pricing practices under Section 301 during Trump's term. The US pharmaceutical tariff threats were a key negotiating tactic that pushed the UK to accept these terms.
BMJ Analysis: The Human and Financial Cost
Financial Impact on the NHS
The BMJ study, led by researchers Samuel Cross, Karl Claxton, and Andrew Hill, calculates that the extra cost of the trade deal for the UK will reach £8.8 billion per year. Over the full ten-year period from 2026 to 2036, the total additional cost is estimated at £44.7 billion. The NHS currently spends around £14.4 billion per year on innovative medicines (0.3% of GDP). Under the agreement, this must rise to 0.6% of GDP, effectively doubling the pharmaceutical budget.
'The UK government has committed to increasing net prices for new medicines by 25% and doubling the share of GDP spent on innovative drugs. This money must come from somewhere within the fixed NHS budget,' the BMJ researchers note. If the government does not provide additional funding, the NHS will be forced to cut spending on other essential services.
Impact on Patient Mortality
The BMJ analysis projects that without extra funding, the diversion of £44.7 billion away from frontline care will result in 229,000 additional avoidable deaths by 2036. When the knock-on effects on social care are included, the figure rises to 291,000 excess deaths. The majority of these deaths would occur among patients with heart and respiratory conditions, gastrointestinal diseases, and cancer.
The researchers used established health economic models to estimate the mortality impact. They argue that every £1 million diverted from NHS services results in approximately 5.1 additional deaths, based on historical data on NHS productivity and health outcomes. The NHS funding crisis 2026 is already straining services, and this deal could exacerbate the situation.
Government Response and Criticism
The UK Department of Health and Social Care has disputed the BMJ's figures. A spokesperson stated that the trade deal will be financed through funds specifically allocated in the budget, and that a record amount of funding has been secured for the NHS. However, health experts and opposition politicians have expressed deep concern.
The British Medical Association (BMA) has called for the government to publish a full impact assessment. Dr. Emma Runswick, a BMA leader, said: 'This deal prioritises trade interests over patient health. Diverting billions from frontline NHS services to pay for more expensive drugs will inevitably lead to worse outcomes for patients.'
Meanwhile, the US government has hailed the agreement as a victory for American pharmaceutical innovation. U.S. Trade Representative Katherine Tai stated that the deal ensures fair payment for American-developed drugs and strengthens supply chains.
Implications for Europe and Beyond
The US-UK deal sets a precedent that could have far-reaching consequences for other European countries. President Trump has indicated he wants similar arrangements with other nations. The EU pharmaceutical trade negotiations could be next, potentially putting pressure on European healthcare systems that rely on lower drug prices negotiated by public payers.
Pharmaceutical companies like AstraZeneca have already voiced concerns about the deal's impact on Europe. AstraZeneca CEO Pascal Soriot previously stated that the company felt 'chased away' from Europe by pricing policies, and the US-UK deal could accelerate the trend of pharmaceutical investment shifting toward the US and UK.
For the UK, the deal represents a fundamental shift in how medicines are priced and accessed. The long-term consequences for public health, NHS sustainability, and the UK's pharmaceutical industry remain to be seen.
Frequently Asked Questions
What is the US-UK pharmaceutical trade deal?
The US-UK pharmaceutical trade deal, part of the Economic Prosperity Deal signed in December 2025, requires the UK to increase spending on innovative medicines from 0.3% to 0.6% of GDP and raise net prices for new drugs by 25%. In exchange, the US exempts UK pharmaceuticals from import tariffs.
How much will the deal cost the NHS?
According to a BMJ analysis, the deal will cost the NHS an additional £8.8 billion per year, totaling £44.7 billion over ten years (2026-2036).
How many excess deaths are predicted?
The BMJ study estimates 229,000 additional avoidable deaths by 2036 due to diverted NHS funding. Including social care impacts, the figure rises to 291,000.
Why did the UK agree to the deal?
The UK agreed to avoid US import tariffs of up to 100% on British medicines and to secure a broader trade agreement. The deal also aims to attract pharmaceutical investment and improve access to innovative drugs.
Could the deal affect other European countries?
Yes. President Trump has signaled he wants similar deals with other nations, potentially pressuring European healthcare systems to accept higher drug prices.
Follow Discussion